Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

FDA for the treatment of Huntington's disease.
  • Reported positive clinical data from its Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator of the lectin pathway of the immune system. A Phase 2 clinical program to evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of disorders that occurs in the microcirculation of the body's organs, most commonly the kidney and brain, is expected to begin enrollment in early 2014.
  • Announced that its proprietary Cellular Redistribution Assay technology had "unlocked" six additional Class A orphan G protein-coupled receptors (GPCRs) for drug development, bringing the total number of Class A orphan GPCRs "unlocked" by Omeros to 52. These six orphan GPCRs are linked to a series of important indications, including cardiovascular indications, certain types of cancer and Grave's disease. Omeros also announced that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R). Both of these receptors are established drug targets – GLP-1R for diabetes and PTH-1R for osteoporosis.
  • Financial ResultsTotal operating expenses for the quarter ended September 30, 2013 were $13.6 million and included non-cash expenses of $3.2 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $14.5 million, which included non-cash rent and stock-based compensation expenses of $576,000.

    The decrease in total operating expenses for the quarter ended September 30, 2013 compared to the prior year quarter is primarily due to a litigation settlement expense of $3.95 million recorded in the same period in 2012, which was reimbursed by CCIC in the fourth quarter of 2012. For the quarter ended Septemb
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2014)... Australia (PRWEB) September 02, 2014 The ... a cure for chronic tinnitus are seeking support for ... on the Indiegogo platform ( http://igg.me/at/tinaway ), was launched ... be a therapeutic ‘mHealth’ app and is based on ... of a team of biomedical and software engineers, Dr. ...
    (Date:8/31/2014)... September 01, 2014 Available spectra ... needs for research and cultivation of a wide ... Valoya’s proprietary LEDs with proven patented and pending ... uncompromised light uniformity in critical applications in contrast ... LEDs. , “Our customers have a large variety ...
    (Date:8/29/2014)... Electronic circuits are based on electrons, but one of ... photonic circuits, i.e. circuits based on light (photons) instead ... to create a stream of single photons and control ... sorts of attempts to achieve this control, but now ... creating a steady stream of photons emitted one at ...
    (Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and his ... to participate in an investigational study of donor stem ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ... current investigational study must be older than nine months, ...
    Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Breakthrough in light sources for new quantum technology 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
    ... Therapeutics S.A.,(Alternext: ALEHT), a drug and diagnostic discovery ... the annual shareholders, meeting of the Company, that ... de Vezin,s appointment as,member of the Supervisory Board, ... has reached the age limit defined in the ...
    ... 29 ,Anesiva, Inc. (Nasdaq: ANSV ) today ... with Green Vision Company, for,several Middle Eastern countries. ... approved in the U.S. to,provide topical local analgesia ... children three to 18 years of age., ...
    ... barrier technology from Singapore A*STARs Institute of Materials ... organic light emitting diodes (OLEDs) and solar cells ... other technology available in the market, opening up ... , A team of scientists from Singapores Institute ...
    Cached Biology Technology:Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics 2Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics 3Anesiva Announces New Zingo Marketing and Distribution Agreement 2Anesiva Announces New Zingo Marketing and Distribution Agreement 3Nanoengineered barrier invented to protect plastic electronics from water degradation 2Nanoengineered barrier invented to protect plastic electronics from water degradation 3Nanoengineered barrier invented to protect plastic electronics from water degradation 4Nanoengineered barrier invented to protect plastic electronics from water degradation 5
    (Date:8/31/2014)... is developing drugs that are highly effective against a ... patient. Such properties are directly related to the 3D ... have a shape that is perfectly complementary to a ... specificity. Publishing in Nature Chemistry , EPFL scientists ... the 3D structure of bioactive peptides and enhance their ...
    (Date:8/31/2014)... is available in French . ... just published in the prestigious Nature Neuroscience journal ... Centre of the Douglas Mental Health University Institute and McGill ... circuitry and dynamic mechanisms controlling memory as well of the ... sub-region named the subiculum. , In 2009, they developed ...
    (Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
    Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3Memory and Alzheimer's: Towards a better comprehension of the dynamic mechanisms 2CCNY team defines new biodiversity metric 2
    ... published recently in PLoS One delivers new insight ... rattlesnakes may be engaged in an arms race with opossums, ... long been known to eat venomous snakes, this fact has ... of snake venom. Instead, snake venom is usually seen as ...
    ... see if you can spot the tallest tree. If you,re in ... there are few and far between, and tend to hunch low ... forests make the exercise a bit more difficult. And in the ... the eye can estimate. Knowing how tall trees can grow ...
    ... the University of Michigan Comprehensive Cancer Center have found that ... encouraging cancer stem cells to grow. Cancer stem cells ... drive its growth and spread. Traditional cancer treatments do not ... In a study published online in the Journal ...
    Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3MIT: The tallest tree in the land 2MIT: The tallest tree in the land 3Cancer stem cells recruit normal stem cells to fuel ovarian cancer, U-M study finds 2
    ... matrix for the extraction of unwanted ... other macromolecules, Applications: ,Reducing octyl glucoside ... interaction of pure β-adrenergic receptor and ... SDS in 6 M urea/0.05 mM ...
    Values of steady state parameters for enzyme activities are determined....
    ... be used for the identification of potential biomarkers ... and other diseases. Due to the fact that ... it provides an attractive alternative to blood plasma ... ProteoSpin Urine Protein Concentration Micro Kit provides ...
    ... Antibody Capture Kit eliminates ... optimization steps typically required ... This kit enables the ... multiple antigens based on ...
    Biology Products: